These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 33489907

  • 1. Does Multiparametric Magnetic Resonance of Prostate Outperform Risk Calculators in Predicting Prostate Cancer in Biopsy Naïve Patients?
    Falagario UG, Silecchia G, Bruno SM, Di Nauta M, Auciello M, Sanguedolce F, Milillo P, Macarini L, Selvaggio O, Carrieri G, Cormio L.
    Front Oncol; 2020; 10():603384. PubMed ID: 33489907
    [Abstract] [Full Text] [Related]

  • 2. A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators.
    Patel HD, Koehne EL, Shea SM, Fang AM, Gerena M, Gorbonos A, Quek ML, Flanigan RC, Goldberg A, Rais-Bahrami S, Gupta GN.
    BJU Int; 2023 Feb; 131(2):227-235. PubMed ID: 35733400
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Reducing prostate biopsies and magnetic resonance imaging with prostate cancer risk stratification.
    Davik P, Remmers S, Elschot M, Roobol MJ, Bathen TF, Bertilsson H.
    BJUI Compass; 2022 Sep; 3(5):344-353. PubMed ID: 35950035
    [Abstract] [Full Text] [Related]

  • 7. External validation of two mpMRI-risk calculators predicting risk of prostate cancer before biopsy.
    Pallauf M, Steinkohl F, Zimmermann G, Horetzky M, Rajwa P, Pradere B, Lindner AK, Pichler R, Kunit T, Shariat SF, Lusuardi L, Drerup M.
    World J Urol; 2022 Oct; 40(10):2451-2457. PubMed ID: 35941246
    [Abstract] [Full Text] [Related]

  • 8. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
    Alberts AR, Roobol MJ, Verbeek JFM, Schoots IG, Chiu PK, Osses DF, Tijsterman JD, Beerlage HP, Mannaerts CK, Schimmöller L, Albers P, Arsov C.
    Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
    [Abstract] [Full Text] [Related]

  • 9. External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort.
    Chandra Engel J, Palsdottir T, Ankerst D, Remmers S, Mortezavi A, Chellappa V, Egevad L, Grönberg H, Eklund M, Nordström T.
    Eur Urol Open Sci; 2022 Jul; 41():1-7. PubMed ID: 35813248
    [Abstract] [Full Text] [Related]

  • 10. Predictors of clinically significant prostate cancer in biopsy-naïve and prior negative biopsy men with a negative prostate MRI: improving MRI-based screening with a novel risk calculator.
    van Riel LAMJG, Jager A, Meijer D, Postema AW, Smit RS, Vis AN, de Reijke TM, Beerlage HP, Oddens JR.
    Ther Adv Urol; 2022 Jul; 14():17562872221088536. PubMed ID: 35356754
    [Abstract] [Full Text] [Related]

  • 11. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Radtke JP, Wiesenfarth M, Kesch C, Freitag MT, Alt CD, Celik K, Distler F, Roth W, Wieczorek K, Stock C, Duensing S, Roethke MC, Teber D, Schlemmer HP, Hohenfellner M, Bonekamp D, Hadaschik BA.
    Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
    [Abstract] [Full Text] [Related]

  • 12. Head-to-head Comparison of Conventional, and Image- and Biomarker-based Prostate Cancer Risk Calculators.
    Mortezavi A, Palsdottir T, Eklund M, Chellappa V, Murugan SK, Saba K, Ankerst DP, Haug ES, Nordström T.
    Eur Urol Focus; 2021 May; 7(3):546-553. PubMed ID: 32451315
    [Abstract] [Full Text] [Related]

  • 13. Elucidating the need for prostate cancer risk calculators in conjunction with mpMRI in initial risk assessment before prostate biopsy at a tertiary prostate cancer center.
    Krausewitz P, Büttner T, von Danwitz M, Weiten R, Cox A, Klümper N, Stein J, Luetkens J, Kristiansen G, Ritter M, Ellinger J.
    BMC Urol; 2024 Mar 26; 24(1):71. PubMed ID: 38532370
    [Abstract] [Full Text] [Related]

  • 14. European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.
    Foley RW, Maweni RM, Gorman L, Murphy K, Lundon DJ, Durkan G, Power R, O'Brien F, O'Malley KJ, Galvin DJ, Brendan Murphy T, William Watson R.
    BJU Int; 2016 Nov 26; 118(5):706-713. PubMed ID: 26833820
    [Abstract] [Full Text] [Related]

  • 15. Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome.
    Pereira-Azevedo N, Verbeek JFM, Nieboer D, Bangma CH, Roobol MJ.
    Transl Androl Urol; 2018 Feb 26; 7(1):18-26. PubMed ID: 29594016
    [Abstract] [Full Text] [Related]

  • 16. Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators.
    Falagario UG, Martini A, Wajswol E, Treacy PJ, Ratnani P, Jambor I, Anastos H, Lewis S, Haines K, Cormio L, Carrieri G, Rastinehad AR, Wiklund P, Tewari A.
    Eur Urol Oncol; 2020 Oct 26; 3(5):700-704. PubMed ID: 31548130
    [Abstract] [Full Text] [Related]

  • 17. Comparing the prediction of prostate biopsy outcome using the Chinese Prostate Cancer Consortium (CPCC) Risk Calculator and the Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer (ERSPC) Risk Calculator in Chinese and European men.
    Chen R, Verbeek JFM, Yang Y, Song Z, Sun Y, Roobol MJ.
    World J Urol; 2021 Jan 26; 39(1):73-80. PubMed ID: 32279141
    [Abstract] [Full Text] [Related]

  • 18. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.
    Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouvière O.
    Eur Urol; 2017 Aug 26; 72(2):250-266. PubMed ID: 28336078
    [Abstract] [Full Text] [Related]

  • 19. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
    Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, van Leenders AG, Steyerberg EW, Schröder FH.
    Eur Urol; 2012 Mar 26; 61(3):577-83. PubMed ID: 22104592
    [Abstract] [Full Text] [Related]

  • 20. Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer.
    Porpiglia F, Manfredi M, Mele F, Cossu M, Bollito E, Veltri A, Cirillo S, Regge D, Faletti R, Passera R, Fiori C, De Luca S.
    Eur Urol; 2017 Aug 26; 72(2):282-288. PubMed ID: 27574821
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.